openPR Logo
Press release

Global Gene Therapy Market Clinical Trials Research Insight 2028

12-23-2021 11:01 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Gene Therapy Market Clinical Trials Research Insight

Global Gene Therapy Market & Clinical Trials Intelligence Report Highlights

• Global Market Gene Therapy Landscape USD 24 Billion Opportunity
• Comprehensive Commercial & Clinical insight on 16 Approved Gene Therapies
• Gene Therapy Products Dosage & Price Analysis
• Comprehensive Clinical Insight On 1700 Gene Therapies In Clinical Trials
• Information On 45 Orphan Designated Gene Therapies By Indication, Country, Company
• Global Gene Therapy Clinical Trials Insight By Phase, Country, Formulations, Company, Indication, Target
• Global & Regional Market Insight

For Report Sample Contact neeraj@kuickresearch.com

Genes are small fragments of DNA which encode proteins that are used by cell to carry out vital activities. However, the disruptions in DNA sequence of gene can lead to loss or change in cell’s ability to carry out role in the body. This often leads to widespread changes that manifests as disease, including genetic disorders and cancer. The novel gene therapy aims to treat these disorders by replacing, inactivating, or introducing genes in cells which can compensate the activities of abnormal gene.

Several gene therapies have entered the market which has shown to improve survival outcomes in several rare genetic diseases, cancers, and other disorders. Although Spinal Muscular Atrophy (SMA) is a rare disease, it has constituted for the highest share in the market. The development of gene therapy, Zolgensma (AVXS-101), has significantly proven its efficiency in the treatment of SMA, along with changing the disease phenotype. In May 2019, Novartis received approval from the U.S. FDA for Zolgensma, which is designed to address the root cause of SMA. Zolgensma is the first and only approved gene therapy in this segment. Apart from this, the emergence of CAR T cell therapy in the management of cancer has also shown encouraging response in the market.

Currently the field of gene therapy is highly unexplored and researchers are conducting research and development to drive the sector. Much of the innovation and development in the space is being driven by smaller biotech companies or research universities, sometimes in partnership with big pharmaceutical or an entity specialized in the targeted therapy. For instance, in December 2021, BioMarin Pharmaceutical and Skyline Therapeutics announced a multi-year global strategic collaboration for the discovery, development and commercialization of Adeno-Associated Virus (AAV) gene therapies to treat genetic cardiovascular diseases. In addition, Decibel Therapeutics collaborated with Regeneron to discover and develop gene therapies for hearing loss. These rising trends in the market help to increase the investment, which further boosts the growth of market.

At present, more than 1500 clinical trials are ongoing which are evaluating the role of gene therapies in wide range of therapeutic conditions including neurological diseases, ocular disorders, Alzheimer’s disease, HIV/AIDs, Parkinson Disease, and cancers. Chimeric antigen receptor (CAR) T-cell therapy accounts for more than 50% of the clinical pipeline. Several researches are going to expand their use in solid tumors and to overcome the limitations of previously approved CAR T-cell products. Recently, researchers have developed bispecific CAR T cells to enhance the efficacy and specificity, which are present in initial stages of development.

The promising future of gene therapies is driven by improvement and advancement of the underpinning technologies and cellular mechanisms, such as improvements in the safety of gene editing tools, fine-tuning of regulating mechanisms designed into cells, or the use of cells to deliver drugs in a controlled and targeted way. Further, recent scientific and technological advances have also aid in reducing the development time for personalized treatment making it more available and accessible. The drug development industry is moving rapidly towards precision medicine and leading pharmaceutical companies are expecting to increase investment in forthcoming years.

The global gene therapy market is anticipated to grow with high rates during the forecast period. The growing prevalence of chronic diseases, such as cancer and various rare diseases is one of the major factors driving the progress of the market. The pipeline for cancer gene therapy is quite strong and recently several industry players have been focused on developing several effective gene therapies and its vectors, which will further boost the growth of market. As per our analysis, the global gene therapy market is expected to surpass US$ 20 Billion by 2028.

Contact:

Neeraj Chawla
Research Head
Kuick research
neeraj@kuickresearch.com
+919810410366

Delhi,
India

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Gene Therapy Market Clinical Trials Research Insight 2028 here

News-ID: 2509211 • Views: 175

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Gene

Gene Synthesis Market by Top Manufacturers - Gene script, Gene Art (Thermofische …
The "Gene Synthesis Market" report Added by "Big Market Research", enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies. In the Gene Synthesis Market 2018 research report professionals describe the different facets of the industry with a specific goal
Gene Therapy Market, by Gene Therapy Type Germline Gene Therapy and Somatic Gene …
Genes are composed of deoxyribonucleic acid (DNA), which contains essential information for producing proteins that are crucial for the optimal functioning of the body. Genetic disorder is the result of gene mutations in which proteins are made incorrectly. Gene therapy is intended to introduce healthy gene into damaged cells to counteract for abnormal genes or to make a protein of interest. Mutated gene causes missing of the important protein, with
Gene Synthesis Market Size 2017-2022 OriGene, Gene Oracle, Genescript
e Global Gene Synthesis Market Research Report 2016 is a professional and in-depth study on the current state of the Gene Synthesis market. Annual estimates and forecasts are provided for the period 2017 through 2022. Also, a six-year historic analysis is provided for these markets. The Global market for Gene Synthesis is expected to reach about 410 million USD by 2022 from 200 million USD in 2017, registering a compounded
Gene Therapy Drug Pipeline Analysis
“Gene Therapy Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of multiple disease based upon Gene Therapy. Research report covers all the ongoing drug development in various development phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Country of Development and detailed analysis on the development process. Insight
Cancer Gene Therapy Market Analysis
The gene therapy market has undergone series of transformation from the initial days of research to current clinical development of drugs for treatment of multiple diseases. The initial studies of gene therapy were conducted mostly on monogenetic diseases, but the focus of the researchers rapidly shifted towards the cancer. The increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for a dominant
Global Gene Editing Technologies Market
Gene editing with engineered nucleases is anticipated to contribute significantly to the global life sciences industry. Gene editing provides application from studying gene functions in plants and animals to gene therapy in humans. Gene editing has more efficiency than many other methods in reverse genetics. Increased development of genetic engineering and increased funding in the field of gene editing is anticipated to drive the growth of the global gene editing